Endothelial Progenitor Cells as Biomarkers of Cardiovascular Pathologies: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jason Zhu and Version 1 by Paul Philipp Heinisch.

Endothelial progenitor cells (EPC) may influence the integrity and stability of the vascular endothelium. Endothelial dysfunction is one of the key mechanisms in CVD. The assessment of endothelial dysfunction in vivo remains a major challenge, especially for a clinical evaluation of the need for therapeutic interventions or for primary prevention of CVD. One of the main challenges is the heterogeneity of this particular cell population. Endothelial cells (EC) can become senescent, and the majority of circulating endothelial cells (CEC) show evidence of apoptosis or necrosis. There are a few viable CECs that have properties similar to those of an endothelial progenitor cell. To use EPC levels as a biomarker for vascular function and cumulative cardiovascular risk, a correct definition of their phenotype, as well as an update on the clinical application and practicability of current isolation methods, are an urgent priority. 

  • endothelial cells
  • progenitors
  • cardiovascular disease
  • biomarker

1. Introduction

Cardiovascular diseases (CVD) such as myocardial infarction (MI), cerebral and peripheral arterial disease (PAD) and arterial hypertension are the leading causes of globalmortality [1,2][1][2].
Coronary artery disease (CAD), leading to narrowing or complete blockage of arterial blood supply to the myocardium, is the most prevalent heart disease [2]. Pharmacological agents, interventional and surgical procedures, as well as diet and lifestyle-related concepts to better control established and newly discovered cardiovascular risk factors, are still not sufficient to prevent the millions of disease-related deaths worldwide every year [1,2,3,4][1][2][3][4].
Known cardiovascular risk factors (CVF) contribute to the cascade of atherogenesis especially by inducing injury and dysfunction in endothelial cells. Endothelial integrity is highly reliable due to repair and renewal by endothelial progenitor cells (EPC) derived from different sources, e.g., bone marrow (BM), circulating endothelial progenitor cells (CEPC) or adventitial residents [5]. The impaired mobilization or depletion of these cells contributes to endothelial dysfunction and CVD progression [6].
Ross’ classic paradigm already stated that endothelial cells (EC) injury is one of the most important stimuli for the development of atherosclerotic plaque [7]. In 1997, Asahara et al. reported the isolation of putative EPC from human peripheral blood, based on the cell-surface expression of CD34 and other endothelial markers and introduced the novel concept of CEPCs. These specific cells were reported to further differentiate, at least in vitro, into endothelial cells [8]. They could be identified at sites of active angiogenesis as well as in various animal models of ischemia [8]. CEPCs contribute to on-going endothelial repair through their ability to form layers of neo-endothelium at the site of injury or to serve as a cellular reservoir to replace dysfunctional endothelium [9].

2. Characterisation and Various Origins of Ecs/ Epcs in Humans

A consensus on the ideal marker for the identification of EPC cell types is lacking. This marker may originate from multiple precursors, such as a haemangioblast (HPC), BM progenitors, tissue-resident mesenchymal stem cells (MSC), and especially, from adipose tissue [20][10], impeding fast and simple isolation [5]. The use of density barrier centrifugation is one method that can be utilised in order to separate mononuclear cells from peripheral blood mononuclear cells (PBMNCs). In most cases, cells are sown onto plates that have been coated with fibronectin and then grown using endothelial growth factors. The remaining spindle-shaped cells not only endocytose acetylated low-density lipoprotein (LDL) but also express EC markers and possess other characteristics of ECs. This is, in addition to the fact that EC indicators are present in these cells [24][11], acquired via antigen transfer from platelets that contaminate isolates of PBMNCs [25][12]. Platelets on mononuclear cell cultures degrade into micro-particles (vesicles that retain specific antigens from the cell of origin) within 7 days, and CD31 expression (along with platelet-specific markers) was present at that time on EPCs, now called putative EPC’-aggregates‘, whereas EPCs were CD31-negative on day 1 [25][12]. Attempts to further purify the cell cultures led to the establishment of new protocols. Using markers such as CD133, combined with CD34 and VEGFR2, ensured that only progenitor cells with vasculogenic properties were identified [26,27][13][14]. Cell labelling with antigen-specific antibodies and fluorescence-activated cell sorting (FACS) to select EPCs was applied [8], while still culturing the cells on fibronectin [25][12]. The CD34+ cells were surrounded by spindle-shaped cells expressing increased EC markers. Through the use of this marker combination, this cell type was successfully isolated from adult peripheral blood, umbilical cord blood, and foetal liver [28][15]. Recent research shows that human CD34+/CD133+/VEGFR2-positive cells are separate primitive haematopoietic progenitors lacking vessel formation ability and expressing CD45, a haemangioblast marker [29,30][16][17] Thereafter, in vitro colony-forming cell assays allowed for the isolation of two cell types: colony-forming unit (CFU)-Hill cells and endothelial colony-forming cells (ECFC). In the ‘Hill assay’ and the ECFC, or ‘Ingram protocol’, monocytic cells isolated from blood samples were cultured for two days on fibronectin-coated dishes and then replated for further cultivation [6,27][6][14]. CFU-Hill cells are phagocytic and express EC-like markers (CD14, CD45, and CD115) but lack proliferative and vasculogenic activity. While lacking CD14, CD45, and CD115, ECFCs express EC markers and have the ability to form capillary-like structures in vitro and vessels in vivo [21][18]. ECFCs have been shown to reside in the arterial wall suggesting that this may be the main origin of these cells [26][13]. In summary, EPCs seem to represent two distinct populations with overlapping antigen expressions (e.g., CD34/VEGFR2): hematopoietic-derived spindle-shaped cells from isolation method I/II, also referred to as circulating angiogenic cells or early EPCs (CFU-Hill colonies), and ECFCs, or late EPCs [31][19]. Late EPCs have a vasculogenic ability in vitro and are well-integrated into membranes, whereas early EPCs act via a paracrine mechanisms [32][20] and might even protect late EPCs from oxidative stress [33][21].

3. Influence on Vascular Pathologies and Role as a Biomarker

At present, there is a lack of information or knowledge regarding cell phenotypes in different diseases as the cells originate from different vascular beds and sources [34][22]. Half of the CECs from healthy controls express CD36, a marker for cells of microvascular origin, whereas in sickle cell anaemia, this percentage increases to 80% [35][23]. Contrastingly, no CD36 could be stained in CECs from patients with acute coronary syndrome, consistent with the macro-vascular origin of these cells [36][24]. Investigating the role of CECs in endothelial injury with regard to plasma markers of endothelial injury (vWf, tissue plasminogen activator, soluble E-selectin) led to a correlation between CECs and vWf in heart failure [37][25]. Almost all types of CVD were associated with hypertension, diabetes, smoking and high cholesterol. These CVFs can contribute to endothelial dysfunction [38,39,40,41,42,43,44,45,46,47,48][26][27][28][29][30][31][32][33][34][35][36]. High homocysteine and ADMA values also showed a negative effect on EPC count [49,50][37][38]. On the other hand, high HDL cholesterol and TG levels correlated with CFU but not with CD34/133+ cell count [51][39]. Statin [52][40] and Angiotensin receptor II inhibitors [53][41], as well as oestrogen levels (high oestrogen levels in women were associated with an increased EPC count [54][42] in animal carotid injury oestrogen-enhanced EPC function [55][43]), glitazones [56][44], erythropoietin [53[41][45][46][47],57,58,59], and PDE5 inhibitors [60][48] all showed beneficial effects. EPC count was also dependent on SDF-1 [61[49][50],62], VEGF [10[51][52],11], NO [63][53], GCS-F and GM-CSF [64,65][54][55] levels. Physical activity at a moderate level was identified to be potentially beneficial for preventing CVD. The increase in EPC count was found to be mediated by eNOS and VEGF, and apoptosis was reduced in the cells [66][56]. Physical activity lead to a higher amount of circulating CD34-positive EPCs in CVD patients [67][57]. Furthermore, this study identified an association of CD34-positive cell count with lower all-cause and cardiovascular mortality [67][57]. Vascular damage progression correlated with EPC count [68][58] just as a decreased amount of CD34-positive but increased amount of CD34+CD133+CD309+ and CD34+CD133+ cells suggested the progression of cerebral small vessel disease [69][59]. EPC count could, therefore, serve as a biomarker for CVD course. A correlation with CAD progression was also found for osteocalcin, a regulator of early EPC. A higher number of CVRFs was associated with a decreased total osteocalcin count. Osteocalcin positivity in EPCs was related to LDL, total cholesterol and TGs in both early and, significantly, in late CAD [70][60]. EPC count could also be used as a marker in treatment monitoring, such as in chronic total coronary artery occlusion since an association with Rentrop grade at baseline and 1 year post operation was discovered [71][61]. Some data still suggest that those “monitoring effects” are mostly seen in the young population. Aging by itself is another depriving factor of EPC [6,63][6][53]. Age directly limits EPC mobilisation but also via VEGF depletion and physiologically lowered NO levels, which contribute to the bad survival and proliferation of EPCs [63,72][53][62]. Moreover, several mechanisms, including the co-existence of CVF, lead to the impaired maintenance of endothelial integrity [73][63]. In elderly CAD patients with stable disease, EPC count was significantly reduced compared to younger patients [74][64]. The mobilisation of EPCs was also lower after a coronary bypass grafting in advanced age [75,76][65][66]. The severity of stable CAD shows an inverse correlation with the total/early EPC number [62,77][50][67]. Additionally, chronic vascular disease appears to have opposite effects on early and late EPC numbers and does not influence their functional capacity [62,77][50][67]. Using EPC as a therapeutic target for CVD may therefore underlay an age-related effect. Early EPC implantation increased neovascularisation in young mice, but not in older mice with elevated cholesterol or other CVD risk factors [78][68].

4. The Role of Epc in Congenital Heart Disease Heart Failure

Mechanisms of heart failure in adult heart disease recently received a lot of research attention, but its pathogenic and prognostic significance in single-ventricle physiology is still unknown [79,80,81][69][70][71]. Congenital cardiac malformations with a single ventricle have a high risk of mortality in the first year of life in such patients and frequently result in late complications developing during this stage of palliative repair [82][72]. Even though single-ventricle reconstruction trials have sought to identify predictors of poor outcomes at three years in patients with single-ventricle physiology based on the types of initial shunt (Norwood procedure with ventriculo-pulmonary Sano shunt or with modified subclavio-pulmonary Blalock shunt) and the timing of stage 2 palliation, a 12-year longitudinal cohort study in patients with Fontan (stage 3 procedure) circulation found that the risk of death or cardiac transplantation was closely associated with poorer ventricular function [83,84][73][74]. No definitive therapy was shown to improve heart function with a chronic volume or pressure overload, which may worsen prognosis for single-ventricle patients [85][75]. However, early phase 1/2 clinical trials utilizing the intracoronary delivery of derived progenitor cells demonstrated dependable and safe outcomes in patients with single ventricle physiology. Except for all-cause mortality after staged procedures, derived cardiac progenitors cells administration improved ventricular function and was linked with fewer late problems in patients with single ventricles. Patients treated with cardiac progenitors cells and those who suffered from heart failure with reduced EF but not heart failure with intact EF may experience a substantial improvement in clinical outcomes [86,87][76][77].

References

  1. Shung-King, M.; Weimann, A.; McCreedy, N.; Tatah, L.; Mapa-Tassou, C.; Muzenda, T.; Govia, I.; Were, V.; Oni, T. Protocol for a Multi-Level Policy Analysis of Non-Communicable Disease Determinants of Diet and Physical Activity: Implications for Low-and Middle-Income Countries in Africa and the Caribbean. Int. J. Environ. Res. Public Health 2021, 18, 13061.
  2. Ralapanawa, U.; Sivakanesan, R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J. Epidemiol. Glob. Health 2021, 11, 169–177.
  3. Heinisch, P.P.; Mihalj, M.; Huber, M.; Schefold, J.C.; Hartmann, A.; Walter, M.; Steinhagen-Thiessen, E.; Schmidli, J.; Stüber, F.; Räber, L.; et al. Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery. Cells 2021, 10, 2829.
  4. Mihalj, M.; Heinisch, P.P.; Huber, M.; Schefold, J.C.; Hartmann, A.; Walter, M.; Steinhagen-Thiessen, E.; Schmidli, J.; Stüber, F.; Räber, L.; et al. Effect of Perioperative Lipid Status on Clinical Outcomes after Cardiac Surgery. Cells 2021, 10, 2717.
  5. Yan, F.; Liu, X.; Ding, H.; Zhang, W. Paracrine mechanisms of endothelial progenitor cells in vascular repair. Acta Histochem. 2021, 124, 151833.
  6. Hill, J.M.; Zalos, G.; Halcox, J.P.; Schenke, W.H.; Waclawiw, M.A.; Quyyumi, A.A.; Finkel, T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003, 348, 593–600.
  7. Ross, R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993, 362, 801–809.
  8. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964–967.
  9. Walter, D.H.; Rittig, K.; Bahlmann, F.H.; Kirchmair, R.; Silver, M.; Murayama, T.; Nishimura, H.; Losordo, D.W.; Asahara, T.; Isner, J.M. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105, 3017–3024.
  10. Saito, N.; Shirado, T.; Funabashi-Eto, H.; Wu, Y.; Mori, M.; Asahi, R.; Yoshimura, K. Purification and characterization of human adipose-resident microvascular endothelial progenitor cells. Sci. Rep. 2022, 12, 1775.
  11. Zhang, S.J.; Zhang, H.; Hou, M.; Zheng, Z.; Zhou, J.; Su, W.; Wei, Y.; Hu, S. Is it possible to obtain “true endothelial progenitor cells” by in vitro culture of bone marrow mononuclear cells? Stem Cells Dev. 2007, 16, 683–690.
  12. Prokopi, M.; Pula, G.; Mayr, U.; Devue, C.; Gallagher, J.; Xiao, Q.; Boulanger, C.M.; Westwood, N.; Urbich, C.; Willeit, J.; et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009, 114, 723–732.
  13. Ingram, D.A.; Mead, L.E.; Moore, D.B.; Woodard, W.; Fenoglio, A.; Yoder, M.C. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 2005, 105, 2783–2786.
  14. Ingram, D.A.; Mead, L.E.; Tanaka, H.; Meade, V.; Fenoglio, A.; Mortell, K.; Pollok, K.; Ferkowicz, M.J.; Gilley, D.; Yoder, M.C. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104, 2752–2760.
  15. Timmermans, F.; Plum, J.; Yoder, M.C.; Ingram, D.A.; Vandekerckhove, B.; Case, J. Endothelial progenitor cells: Identity defined? J. Cell Mol. Med. 2009, 13, 87–102.
  16. Case, J.; Mead, L.E.; Bessler, W.K.; Prater, D.; White, H.A.; Saadatzadeh, M.R.; Bhavsar, J.R.; Yoder, M.C.; Haneline, L.S.; Ingram, D.A. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 2007, 35, 1109–1118.
  17. Timmermans, F.; Van Hauwermeiren, F.; De Smedt, M.; Raedt, R.; Plasschaert, F.; De Buyzere, M.L.; Gillebert, T.C.; Plum, J.; Vandekerckhove, B. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1572–1579.
  18. Yoder, M.C.; Mead, L.E.; Prater, D.; Krier, T.R.; Mroueh, K.N.; Li, F.; Krasich, R.; Temm, C.J.; Prchal, J.T.; Ingram, D.A. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109, 1801–1809.
  19. Kirton, J.P.; Xu, Q. Endothelial precursors in vascular repair. Microvasc. Res. 2010, 79, 193–199.
  20. Hur, J.; Yoon, C.H.; Kim, H.S.; Choi, J.H.; Kang, H.J.; Hwang, K.K.; Oh, B.H.; Lee, M.M.; Park, Y.B. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 288–293.
  21. Yang, Z.; von Ballmoos, M.W.; Faessler, D.; Voelzmann, J.; Ortmann, J.; Diehm, N.; Kalka-Moll, W.; Baumgartner, I.; Di Santo, S.; Kalka, C. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. Atherosclerosis 2010, 211, 103–109.
  22. Medina, R.J.; Barber, C.L.; Sabatier, F.; Dignat-George, F.; Melero-Martin, J.M.; Khosrotehrani, K.; Ohneda, O.; Randi, A.M.; Chan, J.K.Y.; Yamaguchi, T.; et al. Endothelial Progenitors: A Consensus Statement on Nomenclature. Stem Cells Transl. Med. 2017, 6, 1316–1320.
  23. Solovey, A.; Lin, Y.; Browne, P.; Choong, S.; Wayner, E.; Hebbel, R.P. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 1997, 337, 1584–1590.
  24. Mutin, M.; Canavy, I.; Blann, A.; Bory, M.; Sampol, J.; Dignat-George, F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999, 93, 2951–2958.
  25. Lee, K.W.; Lip, G.Y.; Tayebjee, M.; Foster, W.; Blann, A.D. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005, 105, 526–532.
  26. Forgione, M.A.; Leopold, J.A.; Loscalzo, J. Roles of endothelial dysfunction in coronary artery disease. Curr. Opin. Cardiol. 2000, 15, 409–415.
  27. Jambrik, Z.; Venneri, L.; Varga, A.; Rigo, F.; Borges, A.; Picano, E. Peripheral vascular endothelial function testing for the diagnosis of coronary artery disease. Am. Heart J. 2004, 148, 684–689.
  28. Brevetti, G.; Silvestro, A.; Schiano, V.; Chiariello, M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003, 108, 2093–2098.
  29. Perticone, F.; Ceravolo, R.; Pujia, A.; Ventura, G.; Iacopino, S.; Scozzafava, A.; Ferraro, A.; Chello, M.; Mastroroberto, P.; Verdecchia, P.; et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104, 191–196.
  30. Schmieder, R.E.; Weihprecht, H.; Schobel, H.; John, S.; Weidinger, G.; Gatzka, C.; Veelken, R. Is endothelial function of the radial artery altered in human essential hypertension? Am. J. Hypertens. 1997, 10, 323–331.
  31. Zvan, B.; Zaletel, M.; Pogacnik, T.; Kiauta, T. Testing of cerebral endothelium function with L-arginine after stroke. Int. Angiol. 2002, 21, 256–259.
  32. Landmesser, U.; Spiekermann, S.; Dikalov, S.; Tatge, H.; Wilke, R.; Kohler, C.; Harrison, D.G.; Hornig, B.; Drexler, H. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: Role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002, 106, 3073–3078.
  33. de Jong, R.M.; Blanksma, P.K.; Cornel, J.H.; Van den Heuvel, A.F.; Siebelink, H.M.; Vaalburg, W.; van Veldhuisen, D.J. Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease. Am. J. Cardiol. 2003, 91, 497–500.
  34. Marin, F.; Roldan, V.; Climent, V.E.; Ibáñez, A.; García, A.; Marco, P.; Sogorb, F.; Lip, G.Y. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 2004, 90, 1162–1166.
  35. Conway, D.S.; Pearce, L.A.; Chin, B.S.; Hart, R.G.; Lip, G.Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107, 3141–3145.
  36. Conway, D.S.; Pearce, L.A.; Chin, B.S.; Hart, R.G.; Lip, G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors. Circulation 2002, 106, 1962–1967.
  37. Chen, J.Z.; Zhu, J.H.; Wang, X.X.; Zhu, J.H.; Xie, X.D.; Sun, J.; Shang, Y.P.; Guo, X.G.; Dai, H.M.; Hu, S.J. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J. Mol. Cell Cardiol. 2004, 36, 233–239.
  38. Thum, T.; Tsikas, D.; Stein, S.; Schultheiss, M.; Eigenthaler, M.; Anker, S.D.; Poole-Wilson, P.A.; Ertl, G.; Bauersachs, J. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J. Am. Coll. Cardiol. 2005, 46, 1693–1701.
  39. Pellegatta, F.; Bragheri, M.; Grigore, L.; Raselli, S.; Maggi, F.M.; Brambilla, C.; Reduzzi, A.; Pirillo, A.; Norata, G.D.; Catapano, A.L. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. Int. J. Mol. Med. 2006, 17, 203–208.
  40. Dimmeler, S.; Aicher, A.; Vasa, M.; Mildner-Rihm, C.; Adler, K.; Tiemann, M.; Rütten, H.; Fichtlscherer, S.; Martin, H.; Zeiher, A.M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Investig. 2001, 108, 391–397.
  41. Bahlmann, F.H.; de Groot, K.; Mueller, O.; Hertel, B.; Haller, H.; Fliser, D. Stimulation of endothelial progenitor cells: A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005, 45, 526–529.
  42. Strehlow, K.; Werner, N.; Berweiler, J.; Link, A.; Dirnagl, U.; Priller, J.; Laufs, K.; Ghaeni, L.; Milosevic, M.; Böhm, M.; et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003, 107, 3059–3065.
  43. Iwakura, A.; Luedemann, C.; Shastry, S.; Hanley, A.; Kearney, M.; Aikawa, R.; Isner, J.M.; Asahara, T.; Losordo, D.W. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003, 108, 3115–3121.
  44. Pistrosch, F.; Herbrig, K.; Oelschlaegel, U.; Richter, S.; Passauer, J.; Fischer, S.; Gross, P. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005, 183, 163–167.
  45. Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.; Mildner-Rihm, C.; Martin, H.; Zeiher, A.M.; Dimmeler, S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102, 1340–1346.
  46. Bahlmann, F.H.; DeGroot, K.; Duckert, T.; Niemczyk, E.; Bahlmann, E.; Boehm, S.M.; Haller, H.; Fliser, D. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003, 64, 1648–1652.
  47. Bahlmann, F.H.; De Groot, K.; Spandau, J.M.; Landry, A.L.; Hertel, B.; Duckert, T.; Boehm, S.M.; Menne, J.; Haller, H.; Fliser, D. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103, 921–926.
  48. Foresta, C.; Lana, A.; Cabrelle, A.; Ferigo, M.; Caretta, N.; Garolla, A.; Palù, G.; Ferlin, A. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int. J. Impot. Res. 2005, 17, 377–380.
  49. Cun, Y.; Diao, B.; Zhang, Z.; Wang, G.; Yu, J.; Ma, L.; Rao, Z. Role of the stromal cell derived factor-1 in the biological functions of endothelial progenitor cells and its underlying mechanisms. Exp. Ther. Med. 2021, 21, 39.
  50. Xiao, Q.; Ye, S.; Oberhollenzer, F.; Mayr, A.; Jahangiri, M.; Willeit, J.; Kiechl, S.; Xu, Q. SDF1 gene variation is associated with circulating SDF1alpha level and endothelial progenitor cell number: The Bruneck Study. PLoS ONE 2008, 3, e4061.
  51. Hattori, K.; Dias, S.; Heissig, B.; Hackett, N.R.; Lyden, D.; Tateno, M.; Hicklin, D.J.; Zhu, Z.; Witte, L.; Crystal, R.G.; et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 2001, 193, 1005–1014.
  52. Iwaguro, H.; Yamaguchi, J.; Kalka, C.; Murasawa, S.; Masuda, H.; Hayashi, S.; Silver, M.; Li, T.; Isner, J.M.; Asahara, T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002, 105, 732–738.
  53. Aicher, A.; Heeschen, C.; Mildner-Rihm, C.; Urbich, C.; Ihling, C.; Technau-Ihling, K.; Zeiher, A.M.; Dimmeler, S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 2003, 9, 1370–1376.
  54. Takahashi, T.; Kalka, C.; Masuda, H.; Chen, D.; Silver, M.; Kearney, M.; Magner, M.; Isner, J.M.; Asahara, T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 1999, 5, 434–438.
  55. Qiu, C.; Xie, Q.; Zhang, D.; Chen, Q.; Hu, J.; Xu, L. GM-CSF induces cyclin D1 expression and proliferation of endothelial progenitor cells via PI3K and MAPK signaling. Cell Physiol. Biochem. 2014, 33, 784–795.
  56. Laufs, U.; Werner, N.; Link, A.; Endres, M.; Wassmann, S.; Jürgens, K.; Miche, E.; Böhm, M.; Nickenig, G. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004, 109, 220–226.
  57. Muggeridge, D.; Dodd, J.; Ross, M.D. CD34(+) progenitors are predictive of mortality and are associated with physical activity in cardiovascular disease patients. Atherosclerosis 2021, 333, 108–115.
  58. Cassano, V.; Tripepi, G.; Perticone, M.; Miceli, S.; Scopacasa, I.; Armentaro, G.; Greco, M.; Maio, R.; Hribal, M.L.; Sesti, G.; et al. Endothelial progenitor cells predict vascular damage progression in naive hypertensive patients according to sex. Hypertens. Res. 2021, 44, 1451–1461.
  59. Huang, Z.X.; Fang, J.; Zhou, C.H.; Zeng, J.; Yang, D.; Liu, Z. CD34(+) cells and endothelial progenitor cell subpopulations are associated with cerebral small vessel disease burden. Biomark. Med. 2021, 15, 191–200.
  60. Shahrour, H.E.; Al Fahom, S.; Al-Massarani, G.; AlSaadi, A.R.; Magni, P. Osteocalcin-expressing endothelial progenitor cells and serum osteocalcin forms are independent biomarkers of coronary atherosclerotic disease severity in male and female patients. J. Endocrinol. Investig. 2022, 45, 1173–1180.
  61. Flores-Umanzor, E.J.; Ortega-Paz, L.; Cepas-Guillen, P.L.; Giacchi, G.; Padro, T.; Badimon, L.; Sabaté, M.; Brugaletta, S. Endothelial Progenitor Cell Function in Patients with Coronary Chronic Total Occlusion and its Relationship With Collateral Circulation. J. Invasive Cardiol. 2021, 33, E809–E816.
  62. Hoffmann, J.; Haendeler, J.; Aicher, A.; Rössig, L.; Vasa, M.; Zeiher, A.M.; Dimmeler, S. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: Important role of nitric oxide. Circ. Res. 2001, 89, 709–715.
  63. Murasawa, S.; Llevadot, J.; Silver, M.; Isner, J.M.; Losordo, D.W.; Asahara, T. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 2002, 106, 1133–1139.
  64. Scheubel, R.J.; Zorn, H.; Silber, R.E.; Kuss, O.; Morawietz, H.; Holtz, J.; Simm, A. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol. 2003, 42, 2073–2080.
  65. Hamano, K.; Nishida, M.; Hirata, K.; Mikamo, A.; Li, T.S.; Harada, M.; Miura, T.; Matsuzaki, M.; Esato, K. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: Clinical trial and preliminary results. Jpn. Circ. J. 2001, 65, 845–847.
  66. Stamm, C.; Westphal, B.; Kleine, H.D.; Petzsch, M.; Kittner, C.; Klinge, H.; Schümichen, C.; Nienaber, C.A.; Freund, M.; Steinhoff, G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361, 45–46.
  67. Xiao, Q.; Kiechl, S.; Patel, S.; Oberhollenzer, F.; Weger, S.; Mayr, A.; Metzler, B.; Reindl, M.; Hu, Y.; Willeit, J.; et al. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis—Results from a large population-based study. PLoS ONE 2007, 2, e975.
  68. Rauscher, F.M.; Goldschmidt-Clermont, P.J.; Davis, B.H.; Wang, T.; Gregg, D.; Ramaswami, P.; Pippen, A.M.; Annex, B.H.; Dong, C.; Taylor, D.A. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003, 108, 457–463.
  69. Vedin, O.; Lam, C.S.P.; Koh, A.S.; Benson, L.; Teng, T.H.K.; Tay, W.T.; Braun, O.Ö.; Savarese, G.; Dahlström, U.; Lund, L.H. Significance of Ischemic Heart Disease in Patients with Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ. Heart Fail. 2017, 10, e003875.
  70. Ohuchi, H.; Hayama, Y.; Negishi, J.; Noritake, K.; Iwasa, T.; Miyazaki, A.; Yamada, O.; Shiraishi, I. Heart failure with preserved right ventricular ejection fraction in postoperative adults with congenital heart disease: A subtype of severe right ventricular pathophysiology. Int. J. Cardiol. 2016, 212, 223–231.
  71. Sano, T.; Ousaka, D.; Goto, T.; Ishigami, S.; Hirai, K.; Kasahara, S.; Ohtsuki, S.; Sano, S.; Oh, H. Impact of Cardiac Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease. Circ. Res. 2018, 122, 994–1005.
  72. Hinton, R.B.; Ware, S.M. Heart Failure in Pediatric Patients with Congenital Heart Disease. Circ. Res. 2017, 120, 978–994.
  73. Newburger, J.W.; Sleeper, L.A.; Frommelt, P.C.; Pearson, G.D.; Mahle, W.T.; Chen, S.; Dunbar-Masterson, C.; Mital, S.; Williams, I.A.; Ghanayem, N.S.; et al. Transplantation-free survival and interventions at 3 years in the single ventricle reconstruction trial. Circulation 2014, 129, 2013–2020.
  74. Atz, A.M.; Zak, V.; Mahony, L.; Uzark, K.; D’Agincourt, N.; Goldberg, D.J.; Williams, R.V.; Breitbart, R.E.; Colan, S.D.; Burns, K.M.; et al. Longitudinal Outcomes of Patients with Single Ventricle After the Fontan Procedure. J. Am. Coll. Cardiol. 2017, 69, 2735–2744.
  75. Metra, M.; Teerlink, J.R. Heart failure. Lancet 2017, 390, 1981–1995.
  76. Ishigami, S.; Ohtsuki, S.; Eitoku, T.; Ousaka, D.; Kondo, M.; Kurita, Y.; Hirai, K.; Fukushima, Y.; Baba, K.; Goto, T.; et al. Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ. Res. 2017, 120, 1162–1173.
  77. Ishigami, S.; Ohtsuki, S.; Tarui, S.; Ousaka, D.; Eitoku, T.; Kondo, M.; Okuyama, M.; Kobayashi, J.; Baba, K.; Arai, S.; et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: The TICAP prospective phase 1 controlled trial. Circ. Res. 2015, 116, 653–664.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback